|
OBJECTIVE: Tumor angiogenesis in breast cancer growth, invasion and metastasis plays a vital role in tumor angiogenesis is the growth of tumor tissue to provide oxygen and nutrients, as well as to provide the necessary means of tumor metastasis. Studies have shown that in all aspects of tumor angiogenesis as a target for anti-angiogenic therapy can effectively inhibit breast cancer growth, invasion and metastasis, and has a high efficiency, low toxicity, easy-resistant, etc., has become a breast cancer therapeutic areas of research focus. However, angiogenesis is complex and multi-target regulatory processes, often poor efficacy administered alone, looking for points of regulation acting on different drug combination is the way to improve the efficacy of the urgent need to address the problem. This experiment is starting from this point, through animal studies combining Chinese and Western medicine program inhibit breast cancer angiogenesis, medicine thalidomide, Chinese medicine uses ginsenoside Rg3. In this study, by constructing MCF-7 breast cancer nude mice model, the concept of thalidomide combined with ginsenoside Rg3 on tumor xenograft tumor growth, angiogenesis and invasion and to explore both drugs inhibit tumor angiogenesis mechanisms of action, provide a theoretical basis for clinical medicine. Methods: 20 female nude mice, the human breast cancer cells were seeded on the right breast pads under, O.1ml, 5 × 107 个 / ml, established tumor-bearing mouse model. Subject tumor volume grew to 150-200mm3 randomly divided into four groups, each 5. Group A: thalidomide monotherapy group 200mg/kg; B group: Rg3 monotherapy group 5mg/kg; C Group: two-drug combination group thalidomide 200mg/kg Rg3 5mg/kg; D Group: saline control group of equal volume. Treatment methods are every other day, intraperitoneal injection, the treatment time is d1-d21. Nude mice were observed daily during treatment living conditions across the 2nd measuring weight of nude mice, tumor volume calculation. Medication 21 days to continue to observe the animals were sacrificed after 5 days, anatomic tumor mass and weighed rate. Anatomy nude other organs, to observe whether the tumor metastasis. Immunohistochemical determination of tumor VEGF.MVD.MMP-9 expression levels. Results: 1. Thalidomide group nude weight than the saline control group (P = 0.035), Rg3, compared with the control group, no significant body weight of nude mice increased (P gt; 0.05), while the two drugs better to increase the combined weight of nude mice, and has a significant statistical significance (P = 0.007). 2 thalidomide monotherapy group and monotherapy group Rg3 can inhibit tumor growth, compared with the control group, a statistically significant difference (P lt; 0.001), between the two there was no difference in tumor inhibition (P gt; 0.05), while the two-drug combination can better inhibit tumor growth, compared with the control group, a statistically significant difference (P lt; 0.001). The inhibition rate of each group were thalidomide group: 42.21%, Rg3 group: 38.96%, two-drug combination group: 51.95%. 3 thalidomide monotherapy group and Rg3 can cut VEGF, MMP-9 expression and reduce the value of MVD, respectively, compared with the control group, three were statistically significant (P lt; 0.05), but the two comparison between monotherapy, no significant difference (P gt; 0.05), while the two-drug combination group better than monotherapy, compared with the control group, a statistically significant difference (P lt; 0.001). Conclusions: 1. Thalidomide reduced VEGF, MVD and the expression of MMP-9, thereby inhibiting angiogenesis in breast cancer in nude mice. 2 ginsenoside Rg3 by down VEGF, MVD and the expression of MMP-9, to inhibit angiogenesis in breast cancer in nude mice. 3 thalidomide with ginsenoside Rg3 combined application of inhibiting angiogenesis in breast cancer in nude mice have a synergistic effect, can effectively inhibit tumor growth.
|